Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIRNASDAQ:GOSSNASDAQ:IMMPNASDAQ:OSMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.64-2.7%$3.10$2.46▼$4.15$320.07M0.25324,012 shs424,024 shsGOSSGossamer Bio$1.25+0.8%$1.20$0.66▼$1.55$281.86M1.861.46 million shs1.29 million shsIMMPPrima BioMed$1.68-2.3%$1.81$1.32▼$2.72$251.19M1.71191,835 shs112,598 shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals0.00%+6.38%+15.41%+32.01%+12.92%GOSSGossamer Bio0.00%-2.00%-7.89%+49.28%+13.43%IMMPPrima BioMed0.00%+4.27%-8.06%+20.42%-11.86%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVIRAtea Pharmaceuticals2.3155 of 5 stars3.32.00.00.00.62.51.3GOSSGossamer Bio3.6211 of 5 stars3.51.00.04.71.51.70.0IMMPPrima BioMed0.9697 of 5 stars3.51.00.00.00.60.00.0OSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0064.84% UpsideGOSSGossamer Bio 3.00Buy$7.33486.67% UpsideIMMPPrima BioMed 3.00Buy$7.00316.67% UpsideOSMTOsmotica Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OSMT, AVIR, GOSS, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/AGOSSGossamer Bio$114.70M2.48N/AN/A$0.13 per share9.62IMMPPrima BioMed$5.14M47.73N/AN/A$1.05 per share1.60OSMTOsmotica Pharmaceuticals$177.88M0.00N/A1.00$1.50 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)IMMPPrima BioMed-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)OSMTOsmotica Pharmaceuticals-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/ALatest OSMT, AVIR, GOSS, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/AOSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.9419.94GOSSGossamer Bio6.705.715.71IMMPPrima BioMedN/A18.86N/AOSMTOsmotica PharmaceuticalsN/A0.430.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%GOSSGossamer Bio81.23%IMMPPrima BioMed2.32%OSMTOsmotica Pharmaceuticals46.18%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%GOSSGossamer Bio6.70%IMMPPrima BioMed3.07%OSMTOsmotica Pharmaceuticals5.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableGOSSGossamer Bio180227.30 million212.07 millionOptionableIMMPPrima BioMed2,021146.04 million141.56 millionOptionableOSMTOsmotica Pharmaceuticals30262.59 million59.32 millionNot OptionableOSMT, AVIR, GOSS, and IMMP HeadlinesRecent News About These CompaniesDuane Jose Saltmer and Ravindra Deo Narayan of OSMG and OSMT sentenced to jail for $4 million tax evasion schemeSeptember 5, 2024 | townsvillebulletin.com.auTVanda Pharmaceuticals Inc.March 6, 2024 | wsj.comRVL Pharmaceuticals PLC (RVLPQ)December 19, 2023 | investing.comOther OTC Pharmaceuticals - SeychellesOctober 8, 2023 | statista.comSOsmotica Pharmaceuticals is about to announce its earnings — here's what to expectAugust 14, 2023 | markets.businessinsider.comWhat Wall Street expects from Osmotica Pharmaceuticals's earningsMarch 19, 2023 | markets.businessinsider.comGRO Biosciences Appoints Rakhshita Dhar to its Board of DirectorsJanuary 19, 2022 | nz.finance.yahoo.comUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 19, 2022 | finance.yahoo.comOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'January 19, 2022 | benzinga.comOsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 19, 2022 | finance.yahoo.comRVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022January 18, 2022 | finance.yahoo.comFresh Insights On Osmotica Pharmaceuticals plc (OSMT)January 15, 2022 | stocksregister.comSOsmotica Pharmaceuticals plc (OSMT): What Is Good About Stock?January 11, 2022 | marketingsentinel.comMOsmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022January 6, 2022 | finance.yahoo.comBoom Or Bust: What Are Osmotica Pharmaceuticals plc’s (NASDAQ:OSMT) Future Prospects?January 1, 2022 | marketingsentinel.comMOsmotica Pharmaceuticals plc (NASDAQ: OSMT) Shares Rose Recently. However, Trouble May Still Be Lurking.December 27, 2021 | stocksregister.comSOsmotica Pharmaceuticals plc (NASDAQ: OSMT): Why Investors Shouldn’t Ditch OSMT Stock In 2021December 27, 2021 | marketingsentinel.comMOsmotica Pharmaceuticals plc (NASDAQ:OSMT) Shares Plunged 0.00% In A Week – But Will They Keep Going Up?December 23, 2021 | marketingsentinel.comMJames Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More SharesDecember 22, 2021 | nasdaq.comOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceDecember 20, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSMT, AVIR, GOSS, and IMMP Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.64 -0.10 (-2.67%) As of 04:00 PM EasternAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Gossamer Bio NASDAQ:GOSS$1.25 +0.01 (+0.81%) Closing price 04:00 PM EasternExtended Trading$1.26 +0.01 (+0.80%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Prima BioMed NASDAQ:IMMP$1.68 -0.04 (-2.33%) Closing price 04:00 PM EasternExtended Trading$1.68 0.00 (0.00%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Osmotica Pharmaceuticals NASDAQ:OSMTOsmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
